Daglozin^®-M

Therapeutic Segment:
Anti-diabetic

Generic Name:
Dapagliflozin+Metformin HCI

Description:
Daglozin-M (dapagliflozin and metformin HCl) tablets contain two oral antihyperglycemic medications used in the management of type 2 diabetes: dapagliflozin and metformin hydrochloride.

Indication:
Daglozin-M is indicated in adults aged 18 years-74 years with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:

In patients inadequately controlled on their maximally tolerated dose of metformin alone
In combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products.
In patients, already being treated with the combination of dapagliflozin and metformin as separate tablets.

Formulation: